Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sibutramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 16/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 16/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.97 |
| ▸ | HTR2B | P41595 | 1/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sibutramine SCHEMBL7191483 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL7189499 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL7626175 | 1.00 | CYP3A4 (1.00) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL42301 | 0.99 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL4051966 | 0.99 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL4594859 | 0.99 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL3855473 | 0.99 | CYP3A4 (0.97) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL2672138 | 0.98 | SLC6A3 (1.00) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL2955 | 0.98 | SLC6A3 (1.00) | CYP3A4ALOX15TSHRALDH1A1LMNA | |
| Sibutramine SCHEMBL3707643 | 0.98 | SLC6A3 (1.00) | CYP3A4ALOX15TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3044 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114832019-A | Application of akkermansia muciniphila in preparation of pharmaceutical composition for preventing and treating obesity, composition and application thereof | 广州知易生物科技有限公司 | 2022-08-02 | — | — | CN | claimed |
| US-20220170019-A1 | NANOSYSTEM BASED ON MICRORNA FOR TREATING OBSESITY | UNIVERSIDAD DE MÁLAGA (ES) | 2022-06-02 | — | — | US | claimed |
| EP-3960859-A1 | NANOSYSTEM BASED ON MICRORNA FOR TREATING OBSESITY | Servicio Andaluz De Salud (ES) | 2022-03-02 | — | — | EP | claimed |
| CN-111693640-A | Screening method for illegally added compounds in health food | 劲牌有限公司 | 2020-09-22 | — | — | CN | claimed |
| WO-2020165482-A1 | NANOSYSTEM BASED ON MICRORNA FOR TREATING OBSESITY | SERVICIO ANDALUZ DE SALUD (ES) | 2020-08-20 | — | — | WO | claimed |
| CN-108061777-B | Method for detecting residual quantity of 34 illegally added medicines in weight-losing health-care food | 浙江公正检验中心有限公司 | 2020-05-08 | — | — | CN | claimed |
| CN-110505877-A | RNA cancer vaccine | MODERNATX INC | 2019-11-26 | — | — | CN | claimed |
| CN-110505882-A | Compositions and methods for treating cancer with a combination of an antagonist of PD-1 and an anti-CTLA 4 antibody | MERCK SHARP & DOHME | 2019-11-26 | — | — | CN | claimed |
| CN-110418802-A | Cell surface conjugate and relevant cell composition and method | JUNO THERAPEUTICS GMBH | 2019-11-05 | — | — | CN | claimed |
| CN-110382508-A | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | 卡里塞拉生物科学股份公司 | 2019-10-25 | — | — | CN | claimed |
| US-5459164-A | 1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutylamine compounds are administered to improve glucose tolerance; diabetes | BOOTS PHARMACEUTICALS, INC. (US) | 1995-10-17 | — | — | US | claimed |
| WO-1995020949-A1 | IMPROVING GLUCOSE TOLERANCE | BOOTS PHARMACEUTICALS, INC. (US) | 1995-08-10 | — | — | WO | claimed |
| US-5436272-A | Treatment of obesity | THE BOOTS COMPANY (USA), INC. (US) | 1995-07-25 | — | — | US | claimed |
| EP-0397831-B1 | TREATMENT OF OBESITY | The Boots Company PLC (GB) | 1993-09-15 | — | — | EP | claimed |
| US-5068440-A | Crystallization from a solvent | BOOTS COMPANY, PLC (GB) | 1991-11-26 | — | — | US | claimed |
| EP-0397831-A1 | TREATMENT OF OBESITY. | BOOTS CO PLC (GB) | 1990-11-22 | — | — | EP | claimed |
| EP-0230742-B1 | N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate and pharmaceutical compositions containing it | The Boots Company PLC (GB) | 1990-09-26 | — | — | EP | claimed |
| WO-1990006110-A1 | TREATMENT OF OBESITY | THE BOOTS COMPANY PLC (GB) | 1990-06-14 | — | — | WO | claimed |
| US-4929629-A | ANTIDEPRESSANTS, N,N-DIMETHYL-1-(1-(4-CHLOROPHENYL) CYCLOBUTYL)-3-METHYLBUTYLAMINE HYDROCHLORIDE | BOOTS COMPANY, PLC (GB) | 1990-05-29 | — | — | US | claimed |
| EP-0230742-A1 | N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride monohydrate and pharmaceutical compositions containing it | The Boots Company PLC (GB) | 1987-08-05 | — | — | EP | claimed |